NCT02839304已完成不适用
A Prospective, Multicenter Investigation of the Adagio Cryoablation System in Patients With Atrial Fibrillation
Adagio Medical5 个研究点 分布在 3 个国家目标入组 80 人开始时间: 2016年7月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 80
- 试验地点
- 5
- 主要终点
- Technical performance assessed by complete electrical isolation of all pulmonary veins (entrance block).
研究概览
简要总结
The objective of the study is to demonstrate the safety and feasibility of the Adagio Cryoablation System is subjects with Paroxysmal (PAF), Persistent (PsAF) and Long-Standing Persistent Atrial Fibrillation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient is diagnosed with paroxysmal (PAF), persistent, or long standing persistent atrial fibrillation (PsAF) for which an ablation procedure was deemed most appropriate therapy. Paroxysmal AF is defined as recurrent atrial fibrillation (AF) that terminates spontaneously within seven (7) days. Persistent AF is defined as: an episode lasting longer than seven (7) days, but less than one (1) year documented by consecutive ECG recordings of 100% AF greater than seven (7) days apart or an episode requiring electrical or pharmacological cardioversion after 48 hours of AF documented by continuous recording. Long-Standing Persistent AF is defined as continuous AF that lasts longer than one (1) year.
- •Reported incidence of at least one (1) documented episode of symptomatic atrial fibrillation (AF) during the twelve months preceding trial entry (should be documented by rhythm strip or ECG).
- •Failure of at least one anti-arrhythmic medication (AAD) for paroxysmal atrial fibrillation [class I or III, or AV nodal blocking agents such as beta blockers (BB) and calcium channel blockers (CCB)] as evidenced by recurrent symptomatic paroxysmal atrial fibrillation, or intolerable side effects due to AAD.
- •Left atrial size <55 mm in largest dimension as measured and image documented by preoperative imaging (CT, MRI and/or TTE)
- •Left Ventricular Ejection Fraction ≥ 40% (obtained within 12 months prior to the procedure).
- •Anticoagulation therapy: patient is receiving anticoagulation therapy four (4) weeks prior to the ablation procedure (where appropriate) according to 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation.
- •Patient is at least 18 and ≤80 years of age.
- •Patient is able and willing to comply with mandatory pre and post follow-up testing.
- •Patient is able and willing to give informed consent.
排除标准
- •Patient had any previous left atrial ablation.
- •History of any valvular cardiac surgical procedure, atrial septal defect closure device; or left atrial appendage closure device.
- •Coronary artery bypass grafting (CABG) procedure within the last 3 months.
- •Awaiting cardiac transplantation or other cardiac surgery within the next 12 months.
- •Atrial clot/thrombus on imaging such as on a trans-esophageal echocardiogram (TEE) performed within 48 hours of the procedure if deemed appropriate by the investigator.
- •History of a documented thromboembolic event within the past one (1) year.
- •Diagnosed atrial myxoma.
- •Patient has defibrillator implant.
- •Patient has known cryoglobulinemia.
- •Patient has any contraindication for oral anticoagulation.
- •Anaphylactic allergy to contrast media.
- •Significant pulmonary disease, (e.g. restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms.
- •Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study.
- •Acute illness or active systemic infection or sepsis.
- •Unstable angina.
- •Myocardial infarction within the previous three months.
- •History of blood clotting or bleeding abnormalities.
- •Uncontrolled heart failure or New York Heart Association (NYHA) class III or IV heart failure.
- •An intracardiac thrombus, tumor, or other abnormality that precludes catheter introduction or manipulation.
- •Presence of a condition that precludes vascular access
- •Patient has renal dysfunction with glomerular filtration rate < 30 ml/min/1.73m
- •Structural heart disease of clinical significance including congenital heart disease where either the underlying abnormality or its correction prohibits or increases the risk of ablation.
- •Atrial fibrillation (AF) secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause (e.g. surgery, pericarditis).
- •Any history of a cerebrovascular disease, including stroke or Transient Ischemic Attack.
- •Patients with chronic obstructive pulmonary disease (COPD).
- •Continued need for Amiodarone therapy post procedure.
- •Women who are pregnant (by history of menstrual period or pregnancy test if the history is considered unreliable).
- •Any anatomical abnormality of the patient's esophagus which might interfere with esophageal warming balloon insertion, positioning or inflation.
- •Enrollment in an investigational study evaluating another device or drug.
- •Life expectancy less than 12 months.
结局指标
主要结局
Technical performance assessed by complete electrical isolation of all pulmonary veins (entrance block).
时间窗: 1 day
Technical performance assessed by complete linear block of linear lesions if deployed
时间窗: 1 day
The primary safety endpoint will be determined by evaluating the incidence of serious adverse events > 30 days after the procedure
时间窗: 12 months
Technical performance assessed by AF termination targeting driver regions, when applicable
时间窗: 1 day
The primary safety endpoint will be determined by evaluating the incidence of procedural adverse events.
时间窗: 1 day
The primary safety endpoint will be determined by evaluating the incidence of serious adverse events > 7 days after the procedure
时间窗: 30 days
The primary safety endpoint will be determined by evaluating the incidence of serious adverse events within 7 days of procedure
时间窗: 7 days
次要结局
- Performance assessed by total procedure times)(1 day)
- Performance assessed by procedural fluoroscopy times(1 day)
- Performance assessed by ablation times(1 day)
- Performance assessed by complete freedom from documented AF or other atrial tachycardia (>30s), using a Holter monitor at 6-, 9-, and 12 months post ablation, after a single procedure and off AAD (following a 3 month blanking period).(12 months)
- Performance assessed by percentage of RF focal ablation (touch up) to reach the primary performance endpoint.(1 day)
研究者
研究点 (5)
Loading locations...
相似试验
Unknown
不适用
TURBt With Adjuvant Cryoablation to Treat Bladder CancerUrinary Bladder NeoplasmsNCT02760953Huashan Hospital150
招募中
1 期
Safety and Efficacy of Cryoablation With Karelizumab and Apatinib for Multiple Lung CancersLung CancerNCT06607770Zhou Chengzhi20
Unknown
1 期
Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung CancerLung CancerNCT04201990ShiYue Li20
终止
4 期
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's EsophagusBarrett's EsophagusHigh Grade DysplasiaLow Grade DysplasiaNCT00526786CSA Medical, Inc.78
招募中
2 期
Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free)Advanced Intrahepatic CholangiocarcinomaNCT05835245Fudan University30